Search

Michelle S. Horning

Examiner (ID: 18084, Phone: (571)272-9036 , Office: P/1648 )

Most Active Art Unit
1648
Art Unit(s)
1648, 1671
Total Applications
891
Issued Applications
469
Pending Applications
39
Abandoned Applications
386

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 16990239 [patent_doc_number] => 20210228659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => PHAGE THERAPY [patent_app_type] => utility [patent_app_number] => 17/153911 [patent_app_country] => US [patent_app_date] => 2021-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8493 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153911 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/153911
Phage therapy Jan 20, 2021 Issued
Array ( [id] => 17213153 [patent_doc_number] => 20210346489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => VECTOR PRODUCTION [patent_app_type] => utility [patent_app_number] => 17/143953 [patent_app_country] => US [patent_app_date] => 2021-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10435 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17143953 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/143953
Vector production Jan 6, 2021 Issued
Array ( [id] => 17183873 [patent_doc_number] => 20210330758 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => TREATMENT FOR BK POLYOMAVIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 17/135962 [patent_app_country] => US [patent_app_date] => 2020-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8996 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17135962 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/135962
TREATMENT FOR BK POLYOMAVIRUS INFECTION Dec 27, 2020 Abandoned
Array ( [id] => 16778072 [patent_doc_number] => 20210115150 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) [patent_app_type] => utility [patent_app_number] => 17/118062 [patent_app_country] => US [patent_app_date] => 2020-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21540 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17118062 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/118062
ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) Dec 9, 2020 Abandoned
Array ( [id] => 16727860 [patent_doc_number] => 20210095007 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => ANTIBODIES THAT BIND EBOLA GLYCOPROTEIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/112581 [patent_app_country] => US [patent_app_date] => 2020-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38210 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17112581 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/112581
ANTIBODIES THAT BIND EBOLA GLYCOPROTEIN AND USES THEREOF Dec 3, 2020 Abandoned
Array ( [id] => 16900753 [patent_doc_number] => 20210179669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => HEPATITIS E VIRUS ORF2 CAPSID POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/102505 [patent_app_country] => US [patent_app_date] => 2020-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10547 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17102505 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/102505
HEPATITIS E VIRUS ORF2 CAPSID POLYPEPTIDES AND USES THEREOF Nov 23, 2020 Abandoned
Array ( [id] => 19076492 [patent_doc_number] => 11945842 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-02 [patent_title] => Tetravalent dengue vaccine [patent_app_type] => utility [patent_app_number] => 17/077206 [patent_app_country] => US [patent_app_date] => 2020-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 16 [patent_no_of_words] => 5689 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17077206 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/077206
Tetravalent dengue vaccine Oct 21, 2020 Issued
Array ( [id] => 17280917 [patent_doc_number] => 11197930 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-14 [patent_title] => Liquid pharmaceutical composition [patent_app_type] => utility [patent_app_number] => 17/069118 [patent_app_country] => US [patent_app_date] => 2020-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 22 [patent_no_of_words] => 27202 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17069118 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/069118
Liquid pharmaceutical composition Oct 12, 2020 Issued
Array ( [id] => 17280917 [patent_doc_number] => 11197930 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-14 [patent_title] => Liquid pharmaceutical composition [patent_app_type] => utility [patent_app_number] => 17/069118 [patent_app_country] => US [patent_app_date] => 2020-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 22 [patent_no_of_words] => 27202 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17069118 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/069118
Liquid pharmaceutical composition Oct 12, 2020 Issued
Array ( [id] => 17280917 [patent_doc_number] => 11197930 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-14 [patent_title] => Liquid pharmaceutical composition [patent_app_type] => utility [patent_app_number] => 17/069118 [patent_app_country] => US [patent_app_date] => 2020-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 22 [patent_no_of_words] => 27202 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17069118 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/069118
Liquid pharmaceutical composition Oct 12, 2020 Issued
Array ( [id] => 17280917 [patent_doc_number] => 11197930 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-14 [patent_title] => Liquid pharmaceutical composition [patent_app_type] => utility [patent_app_number] => 17/069118 [patent_app_country] => US [patent_app_date] => 2020-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 22 [patent_no_of_words] => 27202 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17069118 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/069118
Liquid pharmaceutical composition Oct 12, 2020 Issued
Array ( [id] => 16627530 [patent_doc_number] => 20210046183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF IMMUNE COMPLEX DISEASE [patent_app_type] => utility [patent_app_number] => 17/064669 [patent_app_country] => US [patent_app_date] => 2020-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40242 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17064669 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/064669
COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF IMMUNE COMPLEX DISEASE Oct 6, 2020 Abandoned
Array ( [id] => 19624343 [patent_doc_number] => 12163150 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Recombinant measles viruses expressing epitopes of antigens of RNA viruses--use for the preparation of vaccine compositions [patent_app_type] => utility [patent_app_number] => 17/063597 [patent_app_country] => US [patent_app_date] => 2020-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 62 [patent_no_of_words] => 21714 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 232 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17063597 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/063597
Recombinant measles viruses expressing epitopes of antigens of RNA viruses--use for the preparation of vaccine compositions Oct 4, 2020 Issued
Array ( [id] => 16614956 [patent_doc_number] => 20210033609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => AN IMMUNOASSAY FOR THE DIAGNOSIS OF VIRAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 16/948825 [patent_app_country] => US [patent_app_date] => 2020-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25104 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16948825 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/948825
Immunoassay for the diagnosis of viral infections Sep 30, 2020 Issued
Array ( [id] => 19104651 [patent_doc_number] => 11957724 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Phage therapy of [patent_app_type] => utility [patent_app_number] => 17/038442 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 14119 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17038442 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/038442
Phage therapy of Sep 29, 2020 Issued
Array ( [id] => 16525565 [patent_doc_number] => 20200399645 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS [patent_app_type] => utility [patent_app_number] => 17/017111 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17017111 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/017111
Optimized vector for delivery in microbial populations Sep 9, 2020 Issued
Array ( [id] => 16525242 [patent_doc_number] => 20200399322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => OPTIMIZED NUCLEIC ACID MOLECULES [patent_app_type] => utility [patent_app_number] => 17/016249 [patent_app_country] => US [patent_app_date] => 2020-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51294 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17016249 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/016249
OPTIMIZED NUCLEIC ACID MOLECULES Sep 8, 2020 Abandoned
Array ( [id] => 16750211 [patent_doc_number] => 20210102220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => RECOMBINANT MEASLES VIRUSES EXPRESSING EPITOPES OF ANTIGENS OF RNA VIRUSES - USE FOR THE PREPARATION OF VACCINE COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/015846 [patent_app_country] => US [patent_app_date] => 2020-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015846 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/015846
RECOMBINANT MEASLES VIRUSES EXPRESSING EPITOPES OF ANTIGENS OF RNA VIRUSES - USE FOR THE PREPARATION OF VACCINE COMPOSITIONS Sep 8, 2020 Abandoned
Array ( [id] => 16525640 [patent_doc_number] => 20200399720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => COMPOSITIONS AND METHODS FOR DETECTING HEV NUCLEIC ACID [patent_app_type] => utility [patent_app_number] => 17/012946 [patent_app_country] => US [patent_app_date] => 2020-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29655 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17012946 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/012946
Compositions and methods for detecting HEV nucleic acid Sep 3, 2020 Issued
Array ( [id] => 18619186 [patent_doc_number] => 11752208 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-12 [patent_title] => Liquid pharmaceutical composition [patent_app_type] => utility [patent_app_number] => 16/990954 [patent_app_country] => US [patent_app_date] => 2020-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 22 [patent_no_of_words] => 26882 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16990954 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/990954
Liquid pharmaceutical composition Aug 10, 2020 Issued
Menu